Penumbra Inc (PEN)

$231.05

-1.64

(-0.7%)▲

Market is closed - opens 7 PM, 05 Oct 2023

Insights on Penumbra Inc

  • Increasing Revenue

    Revenue is up for the last 6 quarters, 203.89M → 261.49M (in $), with an average increase of 4.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 5 quarters, -3.68M → 18.96M (in $), with an average increase of 82.6% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 24.8% return, outperforming this stock by 6.2%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 31.3% return, outperforming this stock by 8.8%

Performance

  • $226.74
    $233.84
    $231.05
    downward going graph

    1.87%

    Downside

    Day's Volatility :3.04%

    Upside

    1.19%

    downward going graph
  • $144.76
    $348.67
    $231.05
    downward going graph

    37.35%

    Downside

    52 Weeks Volatility :58.48%

    Upside

    33.73%

    downward going graph

Returns

PeriodPenumbra IncSector (Health Care)Index (Russel 2000)
3 Months
-31.01%
-3.2%
0.0%
6 Months
-17.14%
-4.3%
1.0%
1 Year
15.81%
0.4%
0.4%
3 Years
22.47%
19.9%
11.8%

Highlights

Market Capitalization
9.3B
Book Value
$27.77
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
0.72
PE Ratio
331.43
PEG Ratio
-62.27
Wall Street Target Price
337.75
Profit Margin
3.11%
Operating Margin TTM
3.86%
Return On Assets TTM
1.64%
Return On Equity TTM
2.86%
Revenue TTM
937.8M
Revenue Per Share TTM
24.6
Quarterly Revenue Growth YOY
25.5%
Gross Profit TTM
535.2M
EBITDA
60.4M
Diluted Eps TTM
0.72
Quarterly Earnings Growth YOY
106.84
EPS Estimate Current Year
1.73
EPS Estimate Next Year
2.78
EPS Estimate Current Quarter
0.28
EPS Estimate Next Quarter
0.43

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Penumbra Inc(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
14
14
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 46.18%

Current $231.05
Target $337.75

Company Financials

FY17Y/Y Change
Revenue
333.8M
↑ 26.75%
Net Income
4.7M
↓ 68.56%
Net Profit Margin
1.4%
↓ 4.23%
FY18Y/Y Change
Revenue
444.9M
↑ 33.31%
Net Income
6.6M
↑ 41.74%
Net Profit Margin
1.48%
↑ 0.08%
FY19Y/Y Change
Revenue
547.4M
↑ 23.03%
Net Income
48.5M
↑ 634.1%
Net Profit Margin
8.85%
↑ 7.37%
FY20Y/Y Change
Revenue
560.4M
↑ 2.38%
Net Income
-15.7M
↓ 132.4%
Net Profit Margin
-2.8%
↓ 11.65%
FY21Y/Y Change
Revenue
747.6M
↑ 33.4%
Net Income
5.3M
↓ 133.65%
Net Profit Margin
0.71%
↑ 3.51%
FY22Y/Y Change
Revenue
847.1M
↑ 13.32%
Net Income
-2.0M
↓ 137.89%
Net Profit Margin
-0.24%
↓ 0.95%
Q1 FY22Q/Q Change
Revenue
203.9M
↓ 0.06%
Net Income
79.0K
↓ 100.32%
Net Profit Margin
0.04%
↑ 12.11%
Q2 FY22Q/Q Change
Revenue
208.3M
↑ 2.18%
Net Income
-3.7M
↓ 4767.09%
Net Profit Margin
-1.77%
↓ 1.81%
Q3 FY22Q/Q Change
Revenue
213.7M
↑ 2.56%
Net Income
-2.3M
↓ 38.41%
Net Profit Margin
-1.06%
↑ 0.71%
Q4 FY22Q/Q Change
Revenue
221.2M
↑ 3.53%
Net Income
3.9M
↓ 270.72%
Net Profit Margin
1.75%
↑ 2.81%
Q1 FY23Q/Q Change
Revenue
241.4M
↑ 9.12%
Net Income
8.6M
↑ 120.84%
Net Profit Margin
3.55%
↑ 1.8%
Q2 FY23Q/Q Change
Revenue
261.5M
↑ 8.33%
Net Income
19.0M
↑ 121.44%
Net Profit Margin
7.25%
↑ 3.7%
FY17Y/Y Change
Total Assets
476.7M
↑ 54.63%
Total Liabilities
76.3M
↑ 82.84%
FY18Y/Y Change
Total Assets
515.0M
↑ 8.04%
Total Liabilities
92.6M
↑ 21.42%
FY19Y/Y Change
Total Assets
665.9M
↑ 29.3%
Total Liabilities
180.3M
↑ 94.71%
FY20Y/Y Change
Total Assets
823.0M
↑ 23.59%
Total Liabilities
185.2M
↑ 2.72%
FY21Y/Y Change
Total Assets
1.2B
↑ 51.19%
Total Liabilities
290.3M
↑ 56.77%
FY22Y/Y Change
Total Assets
1.4B
↑ 10.18%
Total Liabilities
372.0M
↑ 28.14%
Q1 FY22Q/Q Change
Total Assets
1.3B
↑ 4.61%
Total Liabilities
342.3M
↑ 17.89%
Q2 FY22Q/Q Change
Total Assets
1.3B
↑ 2.02%
Total Liabilities
357.9M
↑ 4.56%
Q3 FY22Q/Q Change
Total Assets
1.3B
↓ 0.47%
Total Liabilities
347.8M
↓ 2.8%
Q4 FY22Q/Q Change
Total Assets
1.4B
↑ 3.73%
Total Liabilities
372.0M
↑ 6.95%
Q1 FY23Q/Q Change
Total Assets
1.4B
↑ 1.78%
Total Liabilities
370.8M
↓ 0.32%
Q2 FY23Q/Q Change
Total Assets
1.4B
↑ 2.67%
Total Liabilities
366.0M
↓ 1.31%
FY17Y/Y Change
Operating Cash Flow
12.7M
↓ 199.09%
Investing Cash Flow
-77.7M
↓ 11403.2%
Financing Cash Flow
104.4M
↑ 1364.48%
FY18Y/Y Change
Operating Cash Flow
28.8M
↑ 127.0%
Investing Cash Flow
-385.0K
↓ 99.5%
Financing Cash Flow
-9.8M
↓ 109.41%
FY19Y/Y Change
Operating Cash Flow
26.7M
↓ 7.48%
Investing Cash Flow
-12.7M
↑ 3201.56%
Financing Cash Flow
-9.0M
↓ 8.72%
FY20Y/Y Change
Operating Cash Flow
-33.2M
↓ 224.73%
Investing Cash Flow
-104.1M
↑ 719.36%
Financing Cash Flow
134.9M
↓ 1605.94%
FY21Y/Y Change
Operating Cash Flow
9.5M
↓ 128.58%
Investing Cash Flow
-21.7M
↓ 79.13%
Financing Cash Flow
836.0K
↓ 99.38%
FY22Y/Y Change
Operating Cash Flow
-55.7M
↓ 685.78%
Investing Cash Flow
54.8M
↓ 352.08%
Financing Cash Flow
11.6M
↑ 1290.19%
Q1 FY22Q/Q Change
Operating Cash Flow
-4.5M
↓ 51.31%
Investing Cash Flow
15.7M
↓ 1273.34%
Financing Cash Flow
-2.6M
↓ 189.19%
Q2 FY22Q/Q Change
Operating Cash Flow
-39.6M
↑ 776.72%
Investing Cash Flow
20.7M
↑ 31.5%
Financing Cash Flow
9.1M
↓ 445.74%
Q3 FY22Q/Q Change
Operating Cash Flow
-12.9M
↓ 67.38%
Investing Cash Flow
9.8M
↓ 52.63%
Financing Cash Flow
-603.0K
↓ 106.6%
Q4 FY22Q/Q Change
Operating Cash Flow
1.3M
↓ 110.36%
Investing Cash Flow
54.8M
↑ 459.88%
Financing Cash Flow
5.7M
↓ 1051.08%
Q1 FY23Q/Q Change
Operating Cash Flow
13.1M
↑ 881.97%
Investing Cash Flow
10.7M
↓ 80.45%
Financing Cash Flow
1.4M
↓ 76.01%
Q2 FY23Q/Q Change
Operating Cash Flow
17.1M
↑ 30.24%
Investing Cash Flow
-6.7M
↓ 162.28%
Financing Cash Flow
8.7M
↑ 531.83%

Technicals Summary

Sell

Neutral

Buy

Penumbra Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Penumbra Inc
Penumbra Inc
-11.22%
-17.14%
15.81%
22.47%
69.22%
Stryker Corporation
Stryker Corporation
-7.02%
-7.58%
23.02%
24.2%
52.72%
Boston Scientific Corp.
Boston Scientific Corp.
-3.28%
1.6%
24.79%
31.35%
36.17%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-8.38%
-16.6%
-20.17%
-13.16%
36.53%
Abbott Laboratories
Abbott Laboratories
-5.05%
-8.08%
-7.34%
-11.76%
33.82%
Medtronic Plc
Medtronic Plc
-4.56%
-4.65%
-10.01%
-26.2%
-21.23%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Penumbra Inc
Penumbra Inc
331.43
331.43
-62.27
1.73
0.03
0.02
0.0
27.77
Stryker Corporation
Stryker Corporation
37.55
37.55
2.85
10.36
0.16
0.06
0.01
45.71
Boston Scientific Corp.
Boston Scientific Corp.
88.02
88.02
2.53
2.0
0.05
0.04
0.0
12.46
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
30.88
30.88
3.07
2.55
0.22
0.12
0.0
10.49
Abbott Laboratories
Abbott Laboratories
32.67
32.67
18.76
4.15
0.14
0.06
0.02
21.42
Medtronic Plc
Medtronic Plc
28.7
28.7
3.04
5.28
0.07
0.04
0.04
38.47
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Penumbra Inc
Penumbra Inc
Buy
$9.3B
69.22%
331.43
3.11%
Stryker Corporation
Stryker Corporation
Buy
$101.0B
52.72%
37.55
13.92%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$77.3B
36.17%
88.02
6.81%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$42.1B
36.53%
30.88
24.56%
Abbott Laboratories
Abbott Laboratories
Buy
$166.1B
33.82%
32.67
12.83%
Medtronic Plc
Medtronic Plc
Buy
$103.5B
-21.23%
28.7
11.47%

Institutional Holdings

  • FMR Inc

    13.14%

  • BlackRock Inc

    10.73%

  • Vanguard Group Inc

    9.35%

  • Capital Research Global Investors

    6.76%

  • T. Rowe Price Associates, Inc.

    5.79%

  • State Street Corporation

    2.76%

Company Information

penumbra is a specialty interventional therapies company that develops and markets innovative medical devices to treat challenging medical conditions with significant unmet clinical needs. we design our therapies to provide our specialist physician customers with improved clinical outcomes through faster and safer procedures at significant overall cost savings to the healthcare system. today we have over 1,000 employees with sales operations in north america, europe, australia and asia.

Organization
Penumbra Inc
Employees
3900
CEO
Mr. Adam Elsesser
Industry
Health Technology

Discover More

FAQs